Research programme: central nervous system disorder therapeutics - SciNeuro Pharmaceuticals
Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator SciNeuro Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for research development in CNS-disorders in China
- 14 Dec 2020 Research programme: Central nervous system disorder therapeutics - SciNeuro is available for licensing as of 14 Dec 2020. https://www.scineuro.com/
- 08 Dec 2020 Early research in CNS disorders in China (unspecified route) prior to December 2020